Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients

Clinical Rheumatology

Volumn 33, Issue 5, 2014, Pages 707-711

  De Stefano, Renato ^a   Frati, Elena ^a   De Quattro, Davide ^a   Menza, Luana ^a   Manganelli, Stefania ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Ankylosing spondylitis; Anti TNF alpha; Etanercept; Low doses; Treatment

Indexed keywords

ACUTE PHASE PROTEIN; ETANERCEPT; NONSTEROID ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; ASAS CRITERIA; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RESPIRATORY TRACT INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; UVEITIS; ANTAGONISTS AND INHIBITORS; DRUG ADMINISTRATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902368924     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2372-6     Document Type: Article

References (11)

1. Braun J, Pham T, Sieper J et al (2003) International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817-824 (Pubitemid 37026490)
2. Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) ASAS/EURAL recommendations for the managementof ankylosing spondylitis. Ann Rheum Dis 65:442-452
3. Davis JC Jr, van der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230-3236 (Pubitemid 37409337)
4. Van den Berg R, Stanislawska-Biernat E, Dèsirèe MFM, van der Heijde D (2011) Comparison of recommendations for the use of antitumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide. Rheumatology 50:2270-2277
5. Navarro-Compan V, Moreira V, Ariza-Ariza R et al (2011) Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 30:993-996
6. Lee SH, Lee YA, Hong SJ et al (2008) Etanercept 25mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol 27:179-181
7. Moghimi J, Sheikhvatan M, Semvani V. The use of low dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series. Rheumatol Int doi: 10.1007/s00296-011-1920-0
8. Brandt J, Listing J, Haibel H et al (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44:342-348 (Pubitemid 40361291)
9. Foster C, Tufail F, Waheed N, Chu D, Miserochi E, Baltatzis S et al (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121:437-440 (Pubitemid 36427629)
10. Rosenbaum J (2004) Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 50:3736-3737
11. van der Horst-Bruinsma IE, Nurmohamed MT (2012) Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis 4(6):413-422